| dbo:abstract |
CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and had been undergoing development by a collaboration between Cortex, Shire, and Servier. It was studied as a potential treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD. CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to. (en) CX-516 es un fármaco ampakina y nootrópico que actúa como un modulador alosterico positivo del receptor AMPA que está siendo desarrollado por Cortex y Shire & Servier. Se ha investigado como tratamiento para la enfermedad de Alzheimer bajo la marca Ampalex, y ha sido examinada como tratamiento para el ADHD. El CX-516 fue el primer compuesto ampakina desarrollado por Cortex y si bien mostró una buena actividad in vitro y resultados positivos en pruebas con animales, los ensayos en humanos fueron decepcionantes debido principalmente a la baja potencia y a su corta vida media. Sin embargo, el CX-516 es aún ampliamente utilizado en investigaciones con animales dentro de fármacos ampakinas, y es el compuesto de referencia estándar para comparar medicamentos nuevos y más potentes de esta clase, tales como el y CX-717. (es) |
| dbo:casNumber |
154235-83-3 |
| dbo:chEMBL |
136800 |
| dbo:fdaUniiCode |
Z5QU38B4V9 |
| dbo:kegg |
C13675 |
| dbo:pubchem |
148184 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/CX-516-2D-skeletal.svg?width=300 |
| dbo:wikiPageID |
5172763 (xsd:integer) |
| dbo:wikiPageLength |
2670 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1084613813 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Ampakine dbc:Ampakines dbc:Abandoned_drugs dbc:Piperidines dbc:Stimulants dbr:Shire_(pharmaceutical_company) dbr:Positive_allosteric_modulator dbr:Cortex_Pharmaceuticals dbr:ADHD dbc:Carboxamides dbr:Drug_development dbr:Alzheimer's_disease dbr:Farampator dbr:Nootropic dbc:Quinoxalines dbr:AMPA_receptor dbr:AMPA_receptor_positive_allosteric_modulator dbc:AMPA_receptor_positive_allosteric_modulators dbr:Servier dbr:CX-717 |
| dbp:c |
14 (xsd:integer) |
| dbp:casNumber |
154235 (xsd:integer) |
| dbp:chembl |
136800 (xsd:integer) |
| dbp:chemspiderid |
130635 (xsd:integer) |
| dbp:eliminationHalfLife |
2700.0 |
| dbp:h |
15 (xsd:integer) |
| dbp:iupacName |
6 (xsd:integer) |
| dbp:iupharLigand |
4165 (xsd:integer) |
| dbp:kegg |
13675.0 |
| dbp:n |
3 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pubchem |
148184 (xsd:integer) |
| dbp:smiles |
O=CN3CCCCC3 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
ANDGGVOPIJEHOF-UHFFFAOYSA-N (en) |
| dbp:unii |
Z5QU38B4V9 (en) |
| dbp:verifiedrevid |
443492828 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_journal dbt:Drugbox dbt:Ionotropic_glutamate_receptor_modulators dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite |
| dcterms:subject |
dbc:Ampakines dbc:Abandoned_drugs dbc:Piperidines dbc:Stimulants dbc:Carboxamides dbc:Quinoxalines dbc:AMPA_receptor_positive_allosteric_modulators |
| gold:hypernym |
dbr:Ampakine |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAmides yago:WikicatMolecularFormulas yago:WikicatStimulants yago:Abstraction100002137 yago:Amide114724264 yago:Chemical114806838 yago:Cognition100023271 yago:Communication100033020 yago:Compound114818238 yago:Formula106816935 yago:Information105816287 yago:Material114580897 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:PsychologicalFeature100023100 yago:Relation100031921 dbo:Drug yago:Statement106722453 yago:Stimulation105827684 yago:Substance100019613 umbel-rc:DrugProduct |
| rdfs:comment |
CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and had been undergoing development by a collaboration between Cortex, Shire, and Servier. It was studied as a potential treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD. (en) CX-516 es un fármaco ampakina y nootrópico que actúa como un modulador alosterico positivo del receptor AMPA que está siendo desarrollado por Cortex y Shire & Servier. Se ha investigado como tratamiento para la enfermedad de Alzheimer bajo la marca Ampalex, y ha sido examinada como tratamiento para el ADHD. (es) |
| rdfs:label |
CX-516 (es) CX-516 (en) |
| owl:sameAs |
freebase:CX-516 yago-res:CX-516 wikidata:CX-516 dbpedia-es:CX-516 dbpedia-sh:CX-516 dbpedia-sr:CX-516 https://global.dbpedia.org/id/4eSk7 |
| prov:wasDerivedFrom |
wikipedia-en:CX-516?oldid=1084613813&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/CX-516-2D-skeletal.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:CX-516 |
| is dbo:wikiPageRedirects of |
dbr:C14H15N3O dbr:BDP-12 dbr:Ampalex |
| is dbo:wikiPageWikiLink of |
dbr:Ampakine dbr:Ligand-gated_ion_channel dbr:List_of_investigational_attention_deficit_hyperactivity_disorder_drugs dbr:Mibampator dbr:C14H15N3O dbr:CX-546 dbr:AMPA_receptor dbr:AMPA_receptor_positive_allosteric_modulator dbr:IDRA-21 dbr:Management_of_schizophrenia dbr:Pesampator dbr:Tulrampator dbr:BDP-12 dbr:Ampalex |
| is foaf:primaryTopic of |
wikipedia-en:CX-516 |
